newsfilter
← Latest News
GlobeNewswire·

Cassava Sciences Reports 2024 Financial Results and Provides Business Update

Top-line data for REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer's disease, expected late first-quarter/early second-quarter 2025License agreement brings potential in a new therapeutic application for